ASPI Form 144: Sale of 8,438 Shares Worth $69,192 Listed
Form 144 filing for ASP Isotopes Inc. (ASPI) reports a proposed sale of 8,438 shares of common stock through Independent Trading Group (ITG) on NASDAQ with an aggregate market value of $69,191.60.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Form 144 filing for ASP Isotopes Inc. (ASPI) reports a proposed sale of 8,438 shares of common stock through Independent Trading Group (ITG) on NASDAQ with an aggregate market value of $69,191.60. The filer acquired 300,000 shares on 09/06/2024 as a restricted stock award from the issuer and indicates the securities were granted as equity compensation. The filing shows 91,913,109 shares outstanding for the issuer and lists the approximate sale date as 09/08/2025. No securities were reported sold by the filer in the past three months. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Insights
TL;DR: Small planned sale of equity compensation; immaterial to total share count and unlikely to affect market price materially.
The filing discloses a proposed sale of 8,438 shares valued at $69,191.60 against 91.9 million shares outstanding, representing roughly 0.009% of outstanding shares. The securities were acquired as a restricted stock award on 09/06/2024 and are to be sold through an identified broker on NASDAQ on 09/08/2025. No prior sales in the past three months are reported. From a financial-impact perspective, the announced amount is small relative to the company’s share base and appears to be a routine monetization of equity compensation rather than a signal of company-level stress.
TL;DR: Standard Rule 144 notice for disposition of restricted stock; compliance and disclosure elements appear to be met.
The filer provides required Rule 144 information: acquisition date, nature of acquisition (restricted stock award), amount acquired, intended broker, and planned sale date. The statement affirms no undisclosed material adverse information. The filing includes no indications of accelerated insider selling or aggregated transactions, and no sales in the last three months were reported. Procedurally, this aligns with usual insider disposition disclosure obligations.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Is there any record of securities sold by the filer in the past three months?
What is the approximate date of the planned sale?
AI-generated analysis. How Rhea-AI works. Not financial advice.